OICHARTS
8 AMThe 8 AM report →

AUROPHARMA

Aurobindo Pharma Limited · NSE · INE406A01037 · F&O · lot 550 · 272 sessions on record
₹1,676.80▲ +4.80 · +0.3%from ₹1,672.00 the session before · 1 Oct 2026 close · NSE end of day
Open
₹1,677.90
High
₹1,700.70
Low
₹1,654.20
Day's range
₹472.8% of the previous close
VWAP
₹1,675.44close +0.08% from it
Volume, shares
11 L1.36× the 20-session average
Turnover, ₹ crore
180
Trades
50,00022 shares per trade
Previous close
₹1,672.00+4.80 to the close
Price band, next session
₹1,509.10 – ₹1,844.5010% either side of the close · dynamic, widened in 5% steps when hit
Day range49% of the way up
₹1,654.20₹1,700.70
52-week range91% of the way up
₹1,066.80 8 Oct₹1,740.00 24 Sept

−3.6% from the high · +57% from the low

The desk read · 1 Octexpiry 27 Oct · 26 days
short covering
futures read
price +0.3% · OI −0.5%
+4.10
futures premium, ₹
+0.2% to spot ₹1,676.80
0.55
puts per call, by OI
by volume 0.73
1,700
max pain
+1.4% from the close
▼ −0.5%
futures OI on the day
−110 lots · 23,000 open

Short covering into a 26-day expiry: futures OI −0.5% on a +0.3% day, the most call OI sits at 1,800, the most put OI at 1,700, max pain 1,700.

Futures and options

1 Oct close · lot 550 · NSE end of day

AUROPHARMA futures closed at ₹1,680.90, +0.2% to spot, with 100% of open interest in the 27 Oct contract, and the 1,680 straddle prices a move of about ±5.4% by expiry.

Futures by expiryall 3 contracts NSE lists on the stock · basis against the spot close ₹1,676.80
Futures by expiry, basis against the spot close ₹1,676.80
ExpiryClose ₹Basis ₹ · %Annualised %OI lots · on the dayShare of OI %Contracts traded
27 Oct26 days₹1,680.90+4.10+0.2%+3.4%23,000▼ −0.6% · −130 lots1002,400
23 Nov53 days₹1,689.80+13.00+0.8%+5.3%100▲ +25.9% · +21 lots0.4575
29 Dec89 days₹1,682.00+5.20+0.3%+1.3%7.00.0% · +7.0 lots0.0310

0.48% of futures OI sits beyond the 27 Oct contract · 33 of 46 listed contracts traded · 11,000 option contracts changed hands

Options27 Oct expiry · 26 days

The 1,680 straddle closed at ₹91.05 (call 46.65 + put 44.40), pricing a move of about ±5.4% by the 27 Oct expiry. In the last 253 windows of 19 sessions, AUROPHARMA moved more than that 104 times.

Call OI, lots
7,10039 L shares
Put OI, lots
3,90021 L shares
Puts per call, by OI
0.55by volume 0.73
Max pain
1,700+1.4% from the close
Contracts traded
33 of 46listed for this expiry
Open interest by strike, lotstop three strikes each side
Calls
Strike
Puts
2,000
1,800
1,600
1,700
1,100
1,660
640
560
1,600
590
Open interest added on the day, lotsthree largest additions each side
Calls
Strike
Puts
+140
1,780
+87
1,700
+210
1,680
+77
1,660
+52
1,640
+30
Close ₹ · Nifty 50 rebased to the first close · futures open interest by the day's build-up126 sessions to 1 Oct · axis fixed at 4 × ATR-14 around the last close
272 sessions on file · from 28 Aug
AUROPHARMA close and futures open interest over the last 126 sessions, with Nifty 50 rebased to the first close132715781828axis spans 38%Nifty 50AUROPHARMA1 Apr6 Jul1 OctFutures open interest, lotspeak 41,000126 sessions from 1 Apr to 1 Oct; the price axis spans 38 percent.

The market after the news

close against the last close before each bulletin · Nifty 50 over the same sessions

After the last 8 bulletins, AUROPHARMA closed higher five sessions later in 3 of 8.

Close after each bulletin on the day, one session later and five sessions later, with Nifty 50 and futures open interest
BulletinDay of the news1 session later5 sessions laterFutures OI on the day
30 JunAurobindo Pharma completes acquisition of Lannett Company▼ −1.6%Nifty +0.6% · −2.2 pp▼ −1.1%Nifty +1.3% · −2.4 pp▼ −1.4%Nifty +0.1% · −1.4 pp▲ +0.2%short build-up
20 MayAurobindo Pharma confirms buyback completion and hits 52-week high▲ +1.9%Nifty 0.0% · +1.9 pp▼ −3.6%Nifty +0.3% · −3.8 pp▼ −6.0%Nifty −0.5% · −5.5 pp▲ +1.0%long build-up
20 MayAurobindo Pharma completes ₹800 crore buyback of shares▲ +0.3%Nifty +0.2% · +0.1 pp▲ +2.2%Nifty +0.2% · +2.1 pp▼ −5.1%Nifty +1.2% · −6.3 pp▲ +0.2%long build-up
19 MayAurobindo Pharma completes ₹800 crore buyback of equity shares▲ +0.3%Nifty +0.2% · +0.1 pp▲ +2.2%Nifty +0.2% · +2.1 pp▼ −5.1%Nifty +1.2% · −6.3 pp▲ +0.2%long build-up
19 MayGland Pharma boosts drug stocks as weak rupee enhances margins▲ +0.8%Nifty −0.1% · +1.0 pp▲ +1.1%Nifty 0.0% · +1.1 pp▼ −2.6%Nifty +1.1% · −3.7 pp▼ −0.7%short covering
9 MayAurobindo Pharma completes ₹800 crore share buyback▼ −0.1%Nifty −1.5% · +1.4 pp▲ +0.1%Nifty −3.3% · +3.4 pp▲ +0.9%Nifty −2.2% · +3.1 pp▼ −0.5%long unwinding
9 MayAurobindo Pharma completes ₹800 crore share buyback▼ −0.1%Nifty −1.5% · +1.4 pp▲ +0.1%Nifty −3.3% · +3.4 pp▲ +0.9%Nifty −2.2% · +3.1 pp▼ −0.5%long unwinding
7 AprAurobindo Pharma approves ₹800 cr share buyback plan▼ −0.8%Nifty +0.7% · −1.5 pp▼ −0.3%Nifty +4.5% · −4.8 pp▲ +2.5%Nifty +5.5% · −3.0 pp▲ +1.2%short build-up
8 of 11 bulletins

Quarterly results

consolidated · latest filed 5 Aug, 09:13 pm IST · NSE filings

Revenue ₹9,150 cr, +16% on a year earlier; profit ₹1,032 cr, +25% in the Jun 2026 quarter, consolidated.

Last 8 quarters, consolidated₹ crore as filed · year on year against the same quarter a year earlier · market: close on the first session after the filing against the last close before it, Nifty 50 over the same session
Quarterly results of AUROPHARMA on the consolidated basis with the market's move on the first session after each filing
QuarterRevenue ₹ crRevenue YoYProfit ₹ crProfit YoYEPS ₹Market on the day
Jun 2026filed 5 Aug₹9,150 cr▲ +16%₹1,032 cr▲ +25%17.86▼ −1.5%Nifty +0.1% · −1.6 pp
Mar 2026filed 21 May₹8,853 cr▲ +5.6%₹921 cr▲ +2.0%15.86▼ −5.4%Nifty +0.3% · −5.7 pp
Dec 2025filed 9 Feb₹8,646 cr▲ +8.4%₹910 cr▲ +7.6%15.67▼ −6.6%Nifty +0.3% · −6.9 pp
Sept 2025filed 5 Nov₹8,286 cr▲ +6.3%₹848 cr▲ +3.8%14.61▼ −0.7%Nifty −0.3% · −0.4 pp
Jun 2025filed 4 Aug₹7,868 cr▲ +4.0%₹824 cr▼ −10%14.20▼ −1.0%Nifty −0.3% · −0.7 pp
Mar 2025filed 27 May₹8,382 cr▲ +11%₹903 cr▼ −0.50%15.56▲ +0.9%Nifty −0.7% · +1.6 pp
Dec 2024filed 6 Feb₹7,979 cr▲ +8.5%₹846 cr▼ −10%14.560.0%Nifty −0.2% · +0.2 pp
Sept 2024filed 9 Nov₹7,796 cr▲ +8.0%₹817 cr▲ +8.7%14.00▼ −2.9%Nifty 0.0% · −2.9 pp
By financial yearApril to March · each year the sum of its four quarters as filed, consolidated · EPS summed across the quarters · only complete years
Financial-year results of AUROPHARMA on the consolidated basis, summed from the quarters filed
YearRevenue ₹ crRevenue YoYProfit ₹ crProfit YoYEPS ₹
FY26to Mar 2026₹33,653 cr▲ +6.1%₹3,503 cr▲ +0.56%60.34
FY25to Mar 2025₹31,724 cr▲ +9.4%₹3,484 cr▲ +9.9%59.81
FY24to Mar 2024₹29,002 cr—₹3,169 cr—54.12

Fundamentals

consolidated · filings to Jun 2026 · close ₹1,676.80 on 1 Oct

AUROPHARMA trades at 26 times trailing earnings against 38 for its industry, 2.5 times book value, revenue +9.1% over twelve months, market cap ₹96,000 cr.

Valuationarithmetic on filings and the close · each cell names what it rests on · — where an input is missing
Market cap
₹96,000 cron 1 Oct · free float ₹46,000 cr
Price to earnings
26consolidated · four quarters to Jun 2026 · industry 38
Trailing EPS
₹64.00diluted · consolidated · four quarters to Jun 2026
Price to book
2.5consolidated · balance sheet to Mar 2026
Book value a share
₹658.40consolidated · balance sheet to Mar 2026 · over NSE's share count
Debt to equity
0.20borrowings over equity · consolidated · balance sheet to Mar 2026
Return on equity
11%trailing profit over average equity · consolidated
Dividend yield
—no dividend with an ex-date in 365 days
Face value
₹1a share
Shares outstanding
58 cron 1 Oct
Growthsums of the four quarters filed to Jun 2026 · growth against the four quarters before them · consolidated
Revenue, trailing 12 months
₹34,935 crfour quarters to Jun 2026
Revenue growth, 12 months
▲ +9.1%against the twelve months before
Revenue 3-year CAGR
▲ +11%trailing twelve months against the twelve months 3 years earlier · consolidated
Profit, trailing 12 months
₹3,711 crfour quarters to Jun 2026
Profit growth, 12 months
▲ +9.5%against the twelve months before
Profit 3-year CAGR
▲ +23%trailing twelve months against the twelve months 3 years earlier · consolidated
PeersBSE sub-group Pharmaceuticals · F&O stocks with filings on record · industry P/E 38, market caps over trailing profit of 13 stocks
Stocks in the BSE sub-group Pharmaceuticals with market cap, price to earnings and price to book
StockMarket cap ₹P/EP/BClose ₹
SUNPHARMASun Pharmaceutical Industries Limited4,30,000 cron 1 Oct36consolidated5.2₹1,801.00
DIVISLABDivi's Laboratories Limited2,50,000 cron 1 Oct52consolidated15₹9,249.00
TORNTPHARMTorrent Pharmaceuticals Limited1,80,000 cron 1 Oct76consolidated10₹4,767.30
ZYDUSLIFEZydus Lifesciences Limited1,10,000 cron 1 Oct26consolidated3.9₹1,145.70
CIPLACipla Limited1,10,000 cron 1 Oct32consolidated3.1₹1,344.00
LAURUSLABSLaurus Labs Limited1,10,000 cron 1 Oct85consolidated20₹1,984.00
MANKINDMankind Pharma Limited1,00,000 cron 1 Oct51consolidated6.3₹2,535.00
DRREDDYDr. Reddy's Laboratories Limited1,00,000 cron 1 Oct31consolidated2.6₹1,206.20
AUROPHARMAAurobindo Pharma Limited96,000 cron 1 Oct26consolidated2.5₹1,676.80
LUPINLupin Limited93,000 cron 1 Oct17consolidated4.1₹2,031.20
GLENMARKGlenmark Pharmaceuticals Limited66,000 cron 1 Oct37consolidated6.3₹2,331.00
ALKEMAlkem Laboratories Limited62,000 cron 1 Oct29consolidated4.3₹5,220.00
BIOCONBiocon Limited60,000 cron 1 Oct110consolidated1.6₹370.70
ABBOTINDIAAbbott India Limited57,000 cron 1 Oct——₹26,840.00
IPCALABIPCA Laboratories Limited49,000 cron 1 Oct—5.2₹1,943.20
GLANDGland Pharma Limited47,000 cron 1 Oct—4.6₹2,874.40
GLAXOGlaxoSmithKline Pharmaceuticals Limited47,000 cron 1 Oct—21₹2,771.10
AJANTPHARMAjanta Pharma Limited45,000 cron 1 Oct—9.9₹3,581.00
EMCUREEmcure Pharmaceuticals Limited37,000 cron 1 Oct—7.4₹1,944.60
WOCKPHARMAWockhardt Limited34,000 cron 1 Oct—6.4₹2,083.90
SAILIFESai Life Sciences Limited33,000 cron 1 Oct—13₹1,541.20
NEULANDLABNeuland Laboratories Limited28,000 cron 1 Oct—15₹21,505.00
RUBICONRubicon Research Limited27,000 cron 1 Oct—21₹1,630.90
PPLPHARMAPiramal Pharma Limited26,000 cron 1 Oct—3.2₹197.95
ACUTAASAcutaas Chemicals Limited26,000 cron 1 Oct—15₹3,196.50
SHILPAMEDShilpa Medicare Limited21,000 cron 1 Oct—8.0₹1,064.10
GRANULESGranules India Limited20,000 cron 1 Oct—4.0₹821.75
CAPLIPOINTCaplin Point Laboratories Limited20,000 cron 1 Oct—5.5₹2,631.90
PFIZERPfizer Limited18,000 cron 1 Oct—4.2₹3,858.90
ONESOURCEOnesource Specialty Pharma Limited17,000 cron 1 Oct—3.0₹1,508.00
COHANCECohance Lifesciences Limited17,000 cron 1 Oct—4.3₹451.30
ALIVUSAlivus Life Sciences Limited17,000 cron 1 Oct—5.1₹1,374.20
ERISEris Lifesciences Limited16,000 cron 1 Oct—4.2₹1,189.80
NATCOPHARMNatco Pharma Limited16,000 cron 1 Oct—1.8₹821.30
APLLTDAlembic Pharmaceuticals Limited16,000 cron 1 Oct—2.8₹815.25
JUBLPHARMAJubilant Pharmova Limited16,000 cron 1 Oct—2.2₹999.30
ASTRAZENAstraZeneca Pharma India Limited15,000 cron 1 Oct—17₹6,031.00
MARKSANSMarksans Pharma Limited15,000 cron 1 Oct—4.8₹325.60
CONCORDBIOConcord Biotech Limited14,000 cron 1 Oct—7.1₹1,374.10
AKUMSAkums Drugs and Pharmaceuticals Limited13,000 cron 1 Oct—3.8₹813.10
CORONACORONA Remedies Limited12,000 cron 1 Oct—17₹2,029.40
BLUEJETBlue Jet Healthcare Limited10,000 cron 1 Oct—7.5₹541.80
VIYASHViyash Scientific Limited10,000 cron 1 Oct—3.3₹231.75
STARStrides Pharma Science Limited10,000 cron 1 Oct—3.2₹1,084.80
PGHLProcter & Gamble Health Limited8,900 cron 1 Oct—17₹5,360.00
AARTIPHARMAarti Pharmalabs Limited8,800 cron 1 Oct—4.1₹968.50
SANOFICONRSanofi Consumer Healthcare India Limited8,700 cron 1 Oct—25₹3,787.20
SYMBIOTECSymbiotec Pharmalab Limited7,700 cron 1 Oct——₹1,198.00
SUPRIYASupriya Lifescience Limited7,500 cron 1 Oct—6.3₹931.00
MOREPENLABMorepen Laboratories Limited7,300 cron 1 Oct—5.9₹133.70
SANOFISanofi India Limited7,000 cron 1 Oct—8.5₹3,037.40
INNOVACAPInnova Captab Limited6,700 cron 1 Oct—6.1₹1,168.00
SPARCSun Pharma Advanced Research Company Limited6,300 cron 1 Oct—4.7₹194.15
SENORESSenores Pharmaceuticals Limited6,200 cron 1 Oct—6.4₹1,349.60
IOLCPIOL Chemicals and Pharmaceuticals Limited6,100 cron 1 Oct—3.4₹209.40
ORCHPHARMAOrchid Pharma Limited5,900 cron 1 Oct—4.6₹990.00
FDCFDC Limited5,500 cron 1 Oct—2.2₹335.90
GUJTHEMGujarat Themis Biosyn Limited5,000 cron 1 Oct——₹381.80
NOVARTINDNovartis India Limited4,900 cron 1 Oct——₹1,965.00
RPGLIFERPG Life Sciences Limited4,800 cron 1 Oct—8.0₹2,930.70
SMSPHARMASMS Pharmaceuticals Limited4,400 cron 1 Oct—5.6₹471.30
GUFICBIOGufic Biosciences Limited4,200 cron 1 Oct—6.3₹418.40
AARTIDRUGSAarti Drugs Limited3,800 cron 1 Oct—2.5₹421.00
UNICHEMLABUnichem Laboratories Limited3,800 cron 1 Oct—1.4₹535.05
KPLKwality Pharmaceuticals Limited3,700 cron 1 Oct——₹3,564.40
SOLARASolara Active Pharma Sciences Limited3,400 cron 1 Oct—2.7₹714.85
INDSWFTLABInd-Swift Laboratories Limited3,400 cron 1 Oct—2.5₹395.15
SHUKRAPHARShukra Pharmaceuticals Limited2,700 cron 1 Oct——₹61.80
HIKALHikal Limited2,700 cron 1 Oct—2.2₹218.15
VENUSREMVenus Remedies Limited2,400 cron 1 Oct—3.6₹1,796.70
DCALDishman Carbogen Amcis Limited2,400 cron 1 Oct—0.35₹150.35
INDOCOIndoco Remedies Limited2,300 cron 1 Oct—2.5₹251.75
SAIPARENTSai Parenterals Limited2,300 cron 1 Oct—4.7₹523.65
SYNCOMFSyncom Formulations (India) Limited2,300 cron 1 Oct—5.4₹23.95
FREDUNFredun Pharmaceuticals Limited2,200 cron 1 Oct——₹1,355.20
WINDLASWindlas Biotech Limited2,200 cron 1 Oct——₹1,082.40
PANACEABIOPanacea Biotec Limited2,200 cron 1 Oct—2.6₹359.05
HESTERBIOHester Biosciences Limited1,800 cron 1 Oct—4.9₹2,126.80
NGLFINENGL Fine-Chem Limited1,800 cron 1 Oct—5.5₹2,924.00
AHCLAnlon Healthcare Limited1,700 cron 1 Oct—6.8₹32.85
FERMENTAFermenta Biotech Limited1,600 cron 1 Oct——₹553.25
JAGSNPHARMJagsonpal Pharmaceuticals Limited1,500 cron 1 Oct—5.5₹231.75
AMRUTANJANAmrutanjan Health Care Limited1,500 cron 1 Oct—4.0₹513.20
KOPRANKopran Limited1,400 cron 1 Oct—2.6₹282.05
BPLPHARMABharat Parenterals Limited1,200 cron 1 Oct——₹1,720.40
LINCOLNLincoln Pharmaceuticals Limited1,200 cron 1 Oct—1.5₹582.05
BAJAJHCAREBajaj Healthcare Limited1,100 cron 1 Oct—2.0₹322.95
SIGACHISigachi Industries Limited1,100 cron 1 Oct—2.0₹28.35
THEMISMEDThemis Medicare Limited1,000 cron 1 Oct—2.6₹113.20
SGRLShree Ganesh Remedies Limited890 cron 1 Oct——₹694.25
ANUHPHRAnuh Pharma Limited860 cron 1 Oct—2.4₹85.85
ZIMLABZim Laboratories Limited740 cron 1 Oct—2.5₹137.00
WANBURYWanbury Limited690 cron 1 Oct—4.8₹198.00
ALBERTDAVDAlbert David Limited490 cron 1 Oct—1.3₹856.70
MEDICAMEQMedicamen Biotech Limited470 cron 17 Sept—1.7₹346.30
HALEOSLABSHALEOS LABS LIMITED450 cron 1 Oct—2.0₹1,490.00
JENBURPHJenburkt Pharmaceuticals Limited400 cron 1 Oct——₹915.25
AAREYDRUGSAarey Drugs & Pharmaceuticals Limited290 cron 1 Oct—2.0₹103.85
NECLIFENectar Lifesciences Limited200 cron 1 Oct—0.34₹10.25
MEDICOMedico Remedies Limited180 cron 1 Oct—2.4₹21.85
BALPHARMABal Pharma Limited170 cron 1 Oct—2.0₹105.75
BROOKSBrooks Laboratories Limited160 cron 1 Oct—1.3₹54.80
KREBSBIOKrebs Biochemicals and Industries Limited150 cron 1 Oct——₹68.05
PARNAXLABParnax Lab Limited130 cron 1 Oct——₹113.15
ALPAAlpa Laboratories Limited120 cron 1 Oct—0.67₹59.25
MAKERSLMakers Laboratories Limited110 cron 1 Oct——₹183.50
SUNLOCSunil Healthcare Limited72 cron 1 Oct——₹70.10
VINEETLABVineet Laboratories Limited69 cron 1 Oct—1.5₹35.90
BIOFILCHEMBiofil Chemicals & Pharmaceuticals Limited48 cron 1 Oct—2.2₹29.30
MANGALAMMangalam Drugs And Organics Limited46 cron 1 Oct—0.45₹29.15
MEDICAPQMedi Caps Limited31 cron 17 Sept——₹24.80
ORTINGLOBEORTIN GLOBAL LIMITED12 cron 1 Oct—9.5₹14.50
AMANTAAmanta Healthcare Limited————
AMBALALSAAmbalal Sarabhai Enterprises Limited————
BAFNAPHBafna Pharmaceuticals Limited————
BLISSGVSBliss GVS Pharma Limited————
KILITCHKilitch Drugs (India) Limited————
LASALasa Supergenerics Limited————
LYKALABSLyka Labs Limited————
NATCAPSUQNatural Capsules Limited————
VALIANTLABValiant Laboratories Limited————
VIVIMEDLABVivimed Labs Limited————

Shareholding

quarter to 30 Jun · 14% of the promoter holding pledged · NSE filings

Promoters hold 51.9%, foreign portfolio investors 16.4%, mutual funds 16.7% and insurance companies 5.0%, as filed for the quarter to 30 Jun.

By category, last 5 quarterspercent of shares · beneath each figure, the change in percentage points against the previous quarter on file
Shareholding of AUROPHARMA by category over the last 5 quarters with the change against the previous quarter
Category30 Jun31 Mar31 Dec30 Sept30 Jun
Promoters51.88▲ +0.06 pp51.820.00 pp51.820.00 pp51.820.00 pp51.82
Foreign portfolio investors16.38▲ +1.14 pp15.24▲ +1.29 pp13.95▼ −0.26 pp14.21▼ −0.17 pp14.38
Mutual funds16.71▼ −1.08 pp17.79▼ −1.73 pp19.52▲ +0.22 pp19.30▲ +0.34 pp18.96
Insurance companies4.99▼ −0.01 pp5.00▼ −0.50 pp5.50▼ −0.37 pp5.87▲ +0.38 pp5.49
Banks and financial institutions3.40▲ +0.32 pp3.08▲ +0.41 pp2.67▲ +0.24 pp2.43▼ −0.05 pp2.48
Individual investors5.74▼ −0.40 pp6.14▲ +0.41 pp5.73▲ +0.12 pp5.61▼ −0.48 pp6.09
Bodies corporate0.49▼ −0.09 pp0.58▲ +0.07 pp0.51▲ +0.05 pp0.46▼ −0.02 pp0.48
Others0.41▲ +0.05 pp0.36▲ +0.05 pp0.31▲ +0.01 pp0.30▼ −0.01 pp0.31

Corporate actions

NSE and BSE records

Nothing upcoming on record; the last was a buyback, ex-date 17 Apr 2026.

Actionsex-dates · upcoming first, then the last eight · dividends in rupees a share, bonus and split as ratios
Corporate actions of AUROPHARMA, upcoming first, then the most recent
Ex-dateActionAmount or ratioRecord dateSource
recent
17 Apr 2026buyback—17 Apr 2026BSE
8 Aug 2025dividend₹4.008 Aug 2025BSE
26 Aug 2024otherAnnual General Meeting——NSE
30 Jul 2024buyback—30 Jul 2024BSE
20 Feb 2024dividend₹1.5020 Feb 2024BSE
20 Nov 2023dividend₹3.0020 Nov 2023BSE
Calendaras notified to the exchange
Next results
—no board meeting notified yet
Dividends in 365 days
—a share · ex-dates inside the year
Last dividend
₹4.00ex-date 8 Aug 2025

Price history

272 sessions on record · to 1 Oct · NSE end of day

AUROPHARMA is +1.7% over 20 sessions against Nifty's −6.2%, 3.6% below its 52-week high, realised volatility 21% annualised.

Returns against Nifty 50longest window first · Nifty 50 over the same sessions
Returns of the stock and Nifty 50 over six windows, longest first
WindowFrom ₹AUROPHARMA %Nifty 50 %Difference pp
250 sessionssince 26 Sept₹1,090.03▲ +54%▼ −9.1%+63
120 sessionssince 9 Apr₹1,340.37▲ +25%▼ −5.7%+31
60 sessionssince 8 Jul₹1,557.35▲ +7.7%▼ −6.1%+14
20 sessionssince 2 Sept₹1,648.12▲ +1.7%▼ −6.2%+8.0
5 sessionssince 24 Sept₹1,715.92▼ −2.3%▼ −2.8%+0.50
1 sessionsince 30 Sept₹1,671.95▲ +0.29%▼ −0.88%+1.2
Averages of the closeclose against each average
5-session average
₹1,691.20close −0.85% from it
20-session average
₹1,686.17close −0.56% from it
50-session average
₹1,643.79close +2.0% from it
200-session average
₹1,414.82close +19% from it
Range and volumetrue range over 14 sessions · high to low over 20 · volume against the 20-session average
Average true range, 14
₹382.3% of the close
Average day's range, 20
₹372.2% of the close
Volume against 20 sessions
1.36×11 L vs 8.1 L average
Volatility and co-movement with Nifty 50annualised from daily log returns · counts share one denominator per cell
Realised volatility, 20
21%≈ ±1.3% a session · moved more than that on 5 of 20
Realised volatility, 60
24%≈ ±1.5% a session · moved more than that on 18 of 60
Realised volatility, 250
26%≈ ±1.6% a session · moved more than that on 62 of 250
Beta to Nifty, 60
0.05moved with Nifty on 28 of 60 sessions
Beta to Nifty, 250
0.37moved with Nifty on 138 of 250 sessions
Up and down sessionscloses above and below the previous close
Last 20 sessions
10 up · 10 downof 20
Last 60 sessions
31 up · 29 downof 60
Last 250 sessions
127 up · 123 downof 250
Best session, 250
▲ +5.0%30 Jan
Worst session, 250
▼ −6.6%10 Feb

Aurobindo Pharma Limited is in 23 NSE indices

all 23 indices

11 bulletins on AUROPHARMA

latest 30 Jun 2026

Beats in the coverage

Often mentioned with

June 2026

Aurobindo Pharma completes acquisition of Lannett CompanyAurobindo Pharma's subsidiary APUSA completed the acquisition of Lannett Company, enhancing its operational capabilities. The deal, effective from 29 June 2026, aims to improve access to essential medicines and includes over 400 new employees from Lannett.High

May 2026

Aurobindo Pharma confirms buyback completion and hits 52-week highAurobindo Pharma confirmed the extinguishment of 5,423,728 shares as part of its ₹800 crore buyback at ₹1,475 per share. The stock also reached a new 52-week high of ₹1,530, drawing investor attention.Medium Aurobindo Pharma completes ₹800 crore buyback of sharesAurobindo Pharma extinguished 54,23,728 equity shares under its ₹800 crore buyback programme at ₹1,475 per share. The buyback was completed between 23 and 29 April 2026, aiming to enhance shareholder value.Medium Aurobindo Pharma completes ₹800 crore buyback of equity sharesAurobindo Pharma extinguished 54,23,728 equity shares under its ₹800 crore buyback programme at ₹1,475 per share. The buyback process was completed on 14 May 2026, potentially enhancing shareholder value and earnings per share.Medium Gland Pharma boosts drug stocks as weak rupee enhances marginsGland Pharma's shares surged 15% as the rupee fell to a record low of 96.34, boosting margins and export revenues. Other pharma stocks also rallied, with gains of 9-16% in recent weeks, benefiting from increased global demand for generics.High Aurobindo Pharma completes ₹800 crore share buybackAurobindo Pharma completed its share buyback of 54,23,728 shares at ₹1,475 each for ₹800 crore, representing 3.93% of its equity capital. The buyback was conducted from 23 to 29 April 2026, enhancing shareholder value.Medium Aurobindo Pharma completes ₹800 crore share buybackAurobindo Pharma completed its buyback of 54,23,728 shares at ₹1,475 each for ₹800 crore. This buyback represents 3.93% of the total paid-up equity share capital, which may enhance shareholder value and market sentiment.Medium

April 2026

Aurobindo Pharma approves ₹800 cr share buyback planAurobindo Pharma's Board approved an ₹800 crore buyback plan for over 54.23 lakh shares at ₹1,475 each, a 10% premium from the previous close. The record date for eligibility is set for April 17, 2026.Medium Aurobindo Pharma approves ₹800 cr share buyback planAurobindo Pharma's Board approved an ₹800 cr buyback plan for 54.23 lakh shares at ₹1,475 each, a 10% premium over the previous close. The record date for eligibility is set for 17 Apr 2026, marking the second buyback in less than two years.Medium

January 2026

Aurobindo Pharma shares rise 6% on import price changesAurobindo Pharma shares rose 6% following the DGFT's Minimum Import Price announcement on key antibiotics. The move is expected to boost the company's pricing power and utilization rates at its manufacturing plant.High Aurobindo Pharma shares rise 6% on import price announcementAurobindo Pharma shares jumped 6% after the government imposed a Minimum Import Price on key antibiotics. The move is expected to boost capacity utilization from 50% to 75%, enhancing pricing power and competitiveness.High

About Aurobindo Pharma Limited

exchange masters as of 18 Sept 2026 · classification by BSE
Company
Aurobindo Pharma Limited
Exchange
NSE · BSE 524804, group A
Listed on NSE
19 Jul 2000
Classification
Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
Index
BSE 200
Face value
₹1 a share
ISIN
INE406A01037
Sessions on record
272
Price source
NSE UDiFF bhavcopy · end of day · delayed
Filings
NSE and BSE public disclosures · results, shareholding and corporate actions as filed
Computed
1 Oct, 09:14 pm IST
Bulletins
11 · written by the desk · not a recommendation

OI Charts is not a SEBI-registered investment adviser or research analyst. Prices, open interest, filings and the desk read are exchange data and arithmetic on it, not a basis for any investment decision.